Intellia Therapeutics’ NTLA-2002 Shows Promise with Potential Stock Surge
JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
Intellia Therapeutics: Promising Outlook with NTLA-2002’s Impressive Phase II Results and Competitive Edge
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...
The Motley Fool6d
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Another promising program, NTLA-2002 for hereditary angioedema (HAE), recently reported positive Phase 2 results. As a result, Intellia recently advanced the candidate into a pivotal Phase 3 trial.
pharmaphorum5d
Is pharma’s interest in orphan drugs waning?
Intellia Therapeutics’ NTLA-2002 for hereditary angioedema, and cancer drugs paltusotine from Crinetics Pharma and bemarituzumab from Amgen. “Even with the anticipated moderation in growth ...
Investing6d
Intellia shares maintain positive stance on PhII trial outcomes
The endorsement follows the success of the company's NTLA-2002 product in meeting all primary and secondary endpoints during its Phase II trials. The analyst highlighted the importance of the ...
American Association of Individual Investors5d
Which Is a Better Investment, Intellia Therapeutics Inc or Syneos Health Inc Stock?
The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 ...
American Association of Individual Investors5d
Which Is a Better Investment, Morphic Holding Inc or Intellia Therapeutics Inc Stock?
The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 ...